Table 1.
Patient characteristics between patients with and without renal recovery
| Recovery (n = 100) | Non-recovery (n = 64) | p value | |
|---|---|---|---|
| Age (years) | 60 (46, 72) | 56 (43, 66) | 0.259 |
| Male gender | 65 (65.0) | 37 (57.8) | 0.410 |
| Body mass index (kg/m2) | 22.9 (20.6, 25.4) | 23.9 (20.4, 27.0) | 0.162 |
| APACHE II score | 13.0 (11, 17) | 17 (12, 22) | 0.014 |
| Non-renal SOFA score | 4 (2, 7) | 6 (3, 10) | 0.026 |
| Hemoglobin (g/L) | 90.0 (82, 102.5) | 91.0 (77, 109.0) | 0.499 |
| Chronic comorbidities | |||
| Diabetes | 18 (18.0) | 12 (18.8) | 1.000 |
| Hypertension | 33 (33.0) | 24 (37.5) | 0.615 |
| COPD | 5 (5.0) | 3 (4.7) | 1.000 |
| Coronary artery disease | 16 (16.0) | 7 (10.9) | 0.490 |
| CKD | 6 (6.0) | 7 (10.9) | 0.374 |
| Chronic liver disease | 33 (33.0) | 25 (39.1) | 0.504 |
| ACEI/ARB | 3 (3.0) | 6 (9.4) | 0.156 |
| Reason for ICU admission | |||
| Surgical | 62 (62.0) | 50 (78.1) | 0.030 |
| Emergency | 24 (24.0) | 5 (7.8) | 0.008 |
| Medical | 14 (14.0) | 9 (14.1) | 0.725 |
| Mechanical ventilation | 84 (84.0) | 51 (79.7) | 0.532 |
| PaO2/FiO2 | 302.5 (192.0, 420.0) | 288.3 (204.3, 413.7) | 0.562 |
| Sepsis | 27 (27.0) | 16 (25.0) | 0.776 |
| Vasopressors | 22 (22.0) | 10 (15.6) | 0.420 |
| Nephrotoxic drugs use | 11 (11.0) | 8 (12.5) | 0.770 |
| Baseline creatinine(µmol/L) | 65.0 (53.9, 76.3) | 65.4 (53.0, 76.0) | 0.915 |
| Serum creatinine diagnosing AKI (µmol/L) | 113.0 (90.9, 144.0) | 135.6 (105.1, 205.1) | 0.001 |
| eGFRa (mL/min/1.73 m2) | 58.6 ± 20.7 | 46.1 ± 22.9 | 0.001 |
| UO 24 h after diagnosing AKI (mL/kg/h) | 0.42 (0.36, 0.47) | 0.27 (0.25, 0.36) | 0.002 |
| AKI classification | |||
| Stage 1 | 73 (73.0) | 18 (28.1) | < 0.001 |
| Stage 2 | 22 (22.0) | 32 (50.0) | |
| Stage 3 | 5 (5.0) | 14 (21.9) | |
| Outcomes | |||
| KRT in ICU | 9 (9) | 19 (30.6) | 0.001 |
| Hospital mortality | 12 (12) | 13 (20.3) | 0.183 |
| 30-Day mortality | 11 (11) | 11 (17.2) | 0.348 |
Values are median (Q1, Q3), mean ± SD or n (%). Nephrotoxic drug primarily includes vancomycin, aminoglycosides, rifampicin, amphotericin B, immunosuppressants and chemotherapy. aGlomerular filtration rate was estimated by the Modification of Diet in Renal Disease formula
APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, ICU intensive care unit, eGFR estimated glomerular filtration rate, UO urine output, AKI acute kidney injury, KRT kidney replacement therapy